Applied Genetic Technologies - AGTC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.39
+0 (0.00%)
Get New Applied Genetic Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGTC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Applied Genetic Technologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.39.

This chart shows the closing price for AGTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Applied Genetic Technologies. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/24/2022WedbushDowngradeOutperform ➝ Neutral
10/24/2022Chardan CapitalDowngradeBuy ➝ Neutral
10/24/2022HC WainwrightDowngradeBuy ➝ Neutral
10/24/2022Stifel NicolausDowngradeBuy ➝ Hold
10/4/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight
9/30/2022Stifel NicolausLower TargetBuy$10.00 ➝ $3.00
9/30/2022HC WainwrightLower TargetBuy$24.00 ➝ $16.00
9/28/2022WedbushReiterated RatingOutperform
9/28/2022BTIG ResearchDowngradeBuy ➝ Neutral
9/28/2022Chardan CapitalLower TargetBuy$5.00 ➝ $3.00
5/17/2022Cantor FitzgeraldReiterated RatingOverweight
4/14/2022Stifel NicolausReiterated RatingBuy$10.00
4/11/2022Chardan CapitalReiterated RatingBuy
2/14/2022Stifel NicolausLower TargetBuy ➝ Buy$10.00
2/8/2022Roth CapitalReiterated RatingBuy
9/24/2021BTIG ResearchReiterated RatingBuy$11.00
9/24/2021WedbushReiterated RatingOutperform
9/24/2021HC WainwrightReiterated RatingBuy$24.00
7/1/2021Chardan CapitalReiterated RatingBuy
6/14/2021BTIG ResearchInitiated CoverageBuy$11.00
3/1/2021Stifel NicolausInitiated CoverageBuy$14.00
2/2/2021HC WainwrightBoost TargetPositive ➝ Buy$18.00 ➝ $24.00
2/1/2021Roth CapitalBoost TargetBuy$30.00 ➝ $35.00
11/20/2020Berenberg BankReiterated RatingBuy$11.00
11/17/2020Roth CapitalBoost TargetBuy$25.00 ➝ $30.00
11/11/2020Berenberg BankInitiated CoverageBuy$15.00
9/9/2020Roth CapitalBoost TargetBuy$25.00 ➝ $26.00
7/22/2020HC WainwrightReiterated RatingBuy$18.00
7/22/2020Chardan CapitalReiterated RatingBuy$7.50
6/22/2020Cantor FitzgeraldInitiated CoverageOverweight$14.00 ➝ $14.00
6/22/2020HC WainwrightReiterated RatingBuy$18.00
5/13/2020HC WainwrightReiterated RatingBuy$18.00
3/11/2020HC WainwrightReiterated RatingBuy
2/6/2020Chardan CapitalUpgradeBuy$10.00
1/27/2020Roth CapitalInitiated CoverageBuy$25.00
1/24/2020Janney Montgomery ScottReiterated RatingOutperform$18.00
1/23/2020HC WainwrightReiterated RatingBuy$18.00
1/9/2020HC WainwrightReiterated RatingBuy$18.00
1/9/2020WedbushReiterated RatingBuy$12.00
1/9/2020BMO Capital MarketsBoost TargetOutperform$9.00 ➝ $16.00
(Data available from 12/8/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/12/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Applied Genetic Technologies logo
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $0.39
Low: $0.39
High: $0.39

50 Day Range

MA: $0.39
Low: $0.37
High: $0.42

52 Week Range

Now: $0.39
Low: $0.23
High: $2.83

Volume

N/A

Average Volume

943,490 shs

Market Capitalization

$26.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Applied Genetic Technologies?

The following Wall Street research analysts have issued stock ratings on Applied Genetic Technologies in the last twelve months: StockNews.com.
View the latest analyst ratings for AGTC.

What is the current price target for Applied Genetic Technologies?

0 Wall Street analysts have set twelve-month price targets for Applied Genetic Technologies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Applied Genetic Technologies in the next year.
View the latest price targets for AGTC.

What is the current consensus analyst rating for Applied Genetic Technologies?

Applied Genetic Technologies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AGTC.

What other companies compete with Applied Genetic Technologies?

How do I contact Applied Genetic Technologies' investor relations team?

Applied Genetic Technologies' physical mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company's listed phone number is (386) 462-2204 and its investor relations email address is [email protected]. The official website for Applied Genetic Technologies is www.agtc.com. Learn More about contacing Applied Genetic Technologies investor relations.